Valuation : AbbVie

Market Cap 451B 389B 365B 333B 627B 43,148B 629B 4,327B 1,688B 21,781B 1,695B 1,658B 72,222B P/E 2026 *
32.6x
P/E 2027 * 24.1x
Enterprise Value 512B 441B 414B 378B 711B 48,929B 714B 4,907B 1,915B 24,699B 1,922B 1,880B 81,899B EV / Sales 2026 *
7.57x
EV / Sales 2027 * 6.84x
Free-Float
95.71%
Yield 2026 *
2.68%
Yield 2027 * 2.82%
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Change 5-day change 1-year change 3-year change Capi.($)
-8.07%-3.48% - - 451B
-1.78%-7.61%+56.69%+107.87% 1,047B
-0.48%-2.51%+49.50%+64.64% 646B
+0.23%-3.55%+20.39%+73.60% 451B
-1.66%-4.86%+35.43%+35.38% 355B
-0.55%-3.00%+21.10%+37.68% 291B
-1.19%-2.21%+1.53%+11.51% 252B
-0.24%-3.30%+49.59%+67.44% 234B
-1.12%-2.54%-20.12%-54.22% 203B
+0.02%-1.75%+27.91%+88.50% 181B
Average -1.48%-2.68%+26.89%+48.05% 406.59B
Weighted average by Cap. -1.71%-3.46%+36.12%+64.24%

Financials

2026 *2027 *
Net sales 67.58B 58.24B 54.6B 49.85B 93.9B 6,459B 94.2B 648B 253B 3,261B 254B 248B 10,812B 73.52B 63.35B 59.4B 54.22B 102B 7,027B 102B 705B 275B 3,547B 276B 270B 11,761B
Net income 13.86B 11.94B 11.2B 10.22B 19.26B 1,325B 19.32B 133B 51.84B 669B 52.04B 50.91B 2,217B 18.91B 16.3B 15.28B 13.95B 26.28B 1,808B 26.36B 181B 70.74B 913B 71.01B 69.47B 3,026B
Net Debt 60.49B 52.12B 48.87B 44.61B 84.04B 5,781B 84.31B 580B 226B 2,918B 227B 222B 9,677B 51.66B 44.52B 41.74B 38.1B 71.78B 4,937B 72.01B 495B 193B 2,492B 194B 190B 8,264B
Logo AbbVie
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA